Phase II trial of patupilone in patients with brain metastases from breast cancer

Neuro-Oncology

Volumn 16, Issue 4, 2014, Pages 579-583

  Peereboom, David M ^a,b   Murphy, Conleth ^c   Ahluwalia, Manmeet S ^a,b   Conlin, Alison ^c   Eichler, April ^a,d   Van Poznak, Catherine ^e   Baar, Joseph ^f   Elson, Paul ^b   Seidman, Andrew D ^c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Brain metastases; Breast cancer; Chemotherapy; Epothilone; Patupilone

Indexed keywords

EPOTHILONE B;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEARTBURN; HUMAN; HYPOKALEMIA; LEPTOMENINX; LIVER METASTASIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; VOMITING; WEIGHT REDUCTION;

BRAIN METASTASES; BREAST CANCER; CHEMOTHERAPY; EPOTHILONE; PATUPILONE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; EPOTHILONES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84896965448     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not305     Document Type: Article

References (28)

1. Lim E, Lin NU. New insights and emerging therapies for breast cancer brain metastases. Oncology (Williston Park). 2012;26:652-659, 663.
2. Melisko ME, Moore DH, Sneed PK, et al. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol. 2008;88:359-365.
3. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972-2977.
4. Karam I, Hamilton S, Nichol A, et al. Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the pre-trastuzumab and trastuzumab eras. Radiat Oncol. 2013;8:12.
5. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015-2025.
6. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science. 2004;305: 866-869.
7. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470:M79-M91.
8. Cheng KL, Bradley T, Budman DR. Novel microtubule-targeting agents - the epothilones. Biologics. 2008;2:789-811.
9. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxolw). J Biol Chem. 1997;272:2534-2541.
10. O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol. 2008;62:1045-1054.
11. Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol. 2005;23:9120-9129.
12. Tsimberidou AM, Takimoto CH, Moulder S, et al. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther. 2011;10:209-217.
13. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107: 1348-1354.
14. Iwamoto FM, Omuro AM, Raizer JJ, et al. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2008;87:85-90.
15. Chi KN, Beardsley E, Eigl BJ, et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol. 2012;23:53-58.
16. Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs. 2011;20:107-117.
17. Oehler C, Frei K, Rushing EJ, et al. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology. 2012;83:1-9.
18. Mozzetti S, Martinelli E, Raspaglio G, et al. Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol. 2012;84:1409-1418.
19. Gan PP, McCarroll JA, Byrne FL, et al. Specific beta-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One. 2011;6:e21717.
20. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatinandetoposideforpatients with brainmetastases frombreast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85:1599-1605.
21. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 1986;58:832-839.
22. Siena S, Crino L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brainmetastases frommelanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol. 2010;21:655-661.
23. Fogh S, Machtay M, Werner-Wasik M, et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2010;77:1009-1016.
24. Nayak L, Abrey L, DeAngelis L, et al. Anopen-label, multi-center, phase II study of patupilone (EPO906), in the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer (NSCLC). Paper presented at: American Academy of Neurology Annual Meeting; March 16, 2013; San Diego, CA.
25. Freedman RA, Bullitt E, Sun L, et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancerand brain metastases. Clin Breast Cancer. 2011;11:376-383.
26. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993-1999.
27. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases fromHER2-positive breast cancer. Clin Cancer Res. 2009;15:1452-1459.
28. Roque DM, Bellone S, English DP, et al. Tubulin-beta-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. 2013;119:2582-2592.